Literature DB >> 27118786

Use of Postexposure Prophylaxis After Occupational Exposure to Zaire ebolavirus.

Karen K Wong1, Richard T Davey2, Angela L Hewlett3, Colleen S Kraft4, Aneesh K Mehta4, Mark J Mulligan4, Allison Beck4, William Dorman5, Christopher J Kratochvil3, Lilin Lai4, Tara N Palmore2, Susan Rogers4, Philip W Smith3, Anthony F Suffredini6, Mark Wolcott5, Ute Ströher1, Timothy M Uyeki1.   

Abstract

From September 2014 to April 2015, 6 persons who had occupational exposures to Zaire ebolavirus in West Africa received investigational agent rVSV-ZEBOV or TKM-100802 for postexposure prophylaxis and were monitored in the United States. All patients experienced self-limited symptoms after postexposure prophylaxis; none developed Ebola virus disease. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Entities:  

Keywords:  Ebola virus; TKM-Ebola; postexposure prophylaxis; vesicular stomatitis virus

Mesh：

Year:  2016        PMID： 27118786      PMCID： PMC4946014          DOI： 10.1093/cid/ciw256

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  14 in total

1.  A Recombinant Vesicular Stomatitis Virus Ebola Vaccine.

Authors:  Jason A Regules; John H Beigel; Kristopher M Paolino; Jocelyn Voell; Amy R Castellano; Zonghui Hu; Paula Muñoz; James E Moon; Richard C Ruck; Jason W Bennett; Patrick S Twomey; Ramiro L Gutiérrez; Shon A Remich; Holly R Hack; Meagan L Wisniewski; Matthew D Josleyn; Steven A Kwilas; Nicole Van Deusen; Olivier Tshiani Mbaya; Yan Zhou; Daphne A Stanley; Wang Jing; Kirsten S Smith; Meng Shi; Julie E Ledgerwood; Barney S Graham; Nancy J Sullivan; Linda L Jagodzinski; Sheila A Peel; Judie B Alimonti; Jay W Hooper; Peter M Silvera; Brian K Martin; Thomas P Monath; W Jay Ramsey; Charles J Link; H Clifford Lane; Nelson L Michael; Richard T Davey; Stephen J Thomas
Journal:  N Engl J Med       Date:  2015-04-01       Impact factor: 91.245

2.  Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany.

Authors:  Stephan Günther; Heinz Feldmann; Thomas W Geisbert; Lisa E Hensley; Pierre E Rollin; Stuart T Nichol; Ute Ströher; Harvey Artsob; Clarence J Peters; Thomas G Ksiazek; Stephan Becker; Jan ter Meulen; Stephan Olschläger; Jonas Schmidt-Chanasit; Hinrich Sudeck; Gerd D Burchard; Stefan Schmiedel
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

3.  Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick.

Authors:  Lilin Lai; Richard Davey; Allison Beck; Yongxian Xu; Anthony F Suffredini; Tara Palmore; Sarah Kabbani; Susan Rogers; Gary Kobinger; Judie Alimonti; Charles J Link; Lewis Rubinson; Ute Ströher; Mark Wolcott; William Dorman; Timothy M Uyeki; Heinz Feldmann; H Clifford Lane; Mark J Mulligan
Journal:  JAMA       Date:  2015 Mar 24-31       Impact factor: 56.272

4.  Characteristics and Clinical Management of a Cluster of 3 Patients With Ebola Virus Disease, Including the First Domestically Acquired Cases in the United States.

Authors:  Allison M Liddell; Richard T Davey; Aneesh K Mehta; Jay B Varkey; Colleen S Kraft; Gebre K Tseggay; Oghenetega Badidi; Andrew C Faust; Katia V Brown; Anthony F Suffredini; Kevin Barrett; Mark J Wolcott; Vincent C Marconi; G Marshall Lyon; Gary L Weinstein; Kenney Weinmeister; Shelby Sutton; Munir Hazbun; César G Albariño; Zachary Reed; Debi Cannon; Ute Ströher; Mark Feldman; Bruce S Ribner; H Clifford Lane; Anthony S Fauci; Timothy M Uyeki
Journal:  Ann Intern Med       Date:  2015-07-21       Impact factor: 25.391

5.  Post-exposure prophylaxis against Ebola virus disease with experimental antiviral agents: a case-series of health-care workers.

Authors:  Michael Jacobs; Emma Aarons; Sanjay Bhagani; Ruaridh Buchanan; Ian Cropley; Susan Hopkins; Rebecca Lester; Daniel Martin; Neal Marshall; Stephen Mepham; Simon Warren; Alison Rodger
Journal:  Lancet Infect Dis       Date:  2015-08-25       Impact factor: 25.071

6.  The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.

Authors:  Angela Huttner; Julie-Anne Dayer; Sabine Yerly; Christophe Combescure; Floriane Auderset; Jules Desmeules; Markus Eickmann; Axel Finckh; Ana Rita Goncalves; Jay W Hooper; Gürkan Kaya; Verena Krähling; Steve Kwilas; Barbara Lemaître; Alain Matthey; Peter Silvera; Stephan Becker; Patricia E Fast; Vasee Moorthy; Marie Paule Kieny; Laurent Kaiser; Claire-Anne Siegrist
Journal:  Lancet Infect Dis       Date:  2015-08-04       Impact factor: 25.071

7.  Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.

Authors:  Ana Maria Henao-Restrepo; Ira M Longini; Matthias Egger; Natalie E Dean; W John Edmunds; Anton Camacho; Miles W Carroll; Moussa Doumbia; Bertrand Draguez; Sophie Duraffour; Godwin Enwere; Rebecca Grais; Stephan Gunther; Stefanie Hossmann; Mandy Kader Kondé; Souleymane Kone; Eeva Kuisma; Myron M Levine; Sema Mandal; Gunnstein Norheim; Ximena Riveros; Aboubacar Soumah; Sven Trelle; Andrea S Vicari; Conall H Watson; Sakoba Kéïta; Marie Paule Kieny; John-Arne Røttingen
Journal:  Lancet       Date:  2015-08-03       Impact factor: 79.321

8.  EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain.

Authors:  Andrea Marzi; Shelly J Robertson; Elaine Haddock; Friederike Feldmann; Patrick W Hanley; Dana P Scott; James E Strong; Gary Kobinger; Sonja M Best; Heinz Feldmann
Journal:  Science       Date:  2015-08-06       Impact factor: 47.728

9.  Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study.

Authors:  Thomas W Geisbert; Amy C H Lee; Marjorie Robbins; Joan B Geisbert; Anna N Honko; Vandana Sood; Joshua C Johnson; Susan de Jong; Iran Tavakoli; Adam Judge; Lisa E Hensley; Ian Maclachlan
Journal:  Lancet       Date:  2010-05-29       Impact factor: 79.321

10.  Ebola virus disease in health care workers--Sierra Leone, 2014.

Authors:  Peter H Kilmarx; Kevin R Clarke; Patricia M Dietz; Mary J Hamel; Farah Husain; Jevon D McFadden; Benjamin J Park; David E Sugerman; Joseph S Bresee; Jonathan Mermin; James McAuley; Amara Jambai
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-12-12       Impact factor: 17.586
View more
  14 in total

1.  The Special Pathogens Research Network: Enabling Research Readiness.

Authors:  Colleen S Kraft; Mark G Kortepeter; Bruce Gordon; Lauren M Sauer; Erica S Shenoy; Daniel P Eiras; LuAnn Larson; Jennifer A Garland; Aneesh K Mehta; Kevin Barrett; Connie S Price; Caroline Croyle; Lauren R West; Brooke Noren; Susan Kline; Christa Arguinchona; Henry Arguinchona; Jonathan D Grein; Chad Connally; Susan McLellan; George F Risi; Timothy M Uyeki; Richard T Davey; Jo Ellen Schweinle; Michelle M Schwedhelm; Melissa Harvey; Richard C Hunt; Christopher J Kratochvil
Journal:  Health Secur       Date:  2019-02-19

2.  Evaluating Promising Investigational Medical Countermeasures: Recommendations in the Absence of Guidelines.

Authors:  Nahid Bhadelia; Lauren Sauer; Theodore J Cieslak; Richard T Davey; Susan McLellan; Timothy M Uyeki; Mark G Kortepeter
Journal:  Health Secur       Date:  2019-02-06

3.  Ebola Virus Shedding and Transmission: Review of Current Evidence.

Authors:  Pauline Vetter; William A Fischer; Manuel Schibler; Michael Jacobs; Daniel G Bausch; Laurent Kaiser
Journal:  J Infect Dis       Date:  2016-07-20       Impact factor: 5.226

Review 4.  Post-exposure treatments for Ebola and Marburg virus infections.

Authors:  Robert W Cross; Chad E Mire; Heinz Feldmann; Thomas W Geisbert
Journal:  Nat Rev Drug Discov       Date:  2018-01-29       Impact factor: 84.694

Review 5.  Post-exposure prophylactic vaccine candidates for the treatment of human Risk Group 4 pathogen infections.

Authors:  James Logue; Ian Crozier; Peter B Jahrling; Jens H Kuhn
Journal:  Expert Rev Vaccines       Date:  2020-01-30       Impact factor: 5.683

Review 6.  Ebola virus disease: Essential clinical knowledge.

Authors:  Mahmoud Tawfik Khalafallah; Omar Ali Aboshady; Shaban Ahmed Moawed; Menna Said Ramadan
Journal:  Avicenna J Med       Date:  2017 Jul-Sep

Review 7.  Persistence and Sexual Transmission of Filoviruses.

Authors:  Brayden G Schindell; Andrew L Webb; Jason Kindrachuk
Journal:  Viruses       Date:  2018-12-02       Impact factor: 5.048

Review 8.  Ebola virus disease and critical illness.

Authors:  Aleksandra Leligdowicz; William A Fischer; Timothy M Uyeki; Thomas E Fletcher; Neill K J Adhikari; Gina Portella; Francois Lamontagne; Christophe Clement; Shevin T Jacob; Lewis Rubinson; Abel Vanderschuren; Jan Hajek; Srinivas Murthy; Mauricio Ferri; Ian Crozier; Elhadj Ibrahima; Marie-Claire Lamah; John S Schieffelin; David Brett-Major; Daniel G Bausch; Nikki Shindo; Adrienne K Chan; Tim O'Dempsey; Sharmistha Mishra; Michael Jacobs; Stuart Dickson; G Marshall Lyon; Robert A Fowler
Journal:  Crit Care       Date:  2016-07-29       Impact factor: 9.097

Review 9.  The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials.

Authors:  Ellen Suder; Wakako Furuyama; Heinz Feldmann; Andrea Marzi; Emmie de Wit
Journal:  Hum Vaccin Immunother       Date:  2018-06-18       Impact factor: 3.452

Review 10.  Ebola virus disease: an update on post-exposure prophylaxis.

Authors:  William A Fischer; Pauline Vetter; Daniel G Bausch; Timothy Burgess; Richard T Davey; Robert Fowler; Frederick G Hayden; Peter B Jahrling; Andre C Kalil; Douglas L Mayers; Aneesh K Mehta; Timothy M Uyeki; Michael Jacobs
Journal:  Lancet Infect Dis       Date:  2017-11-15       Impact factor: 25.071
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.